Human Longevity Inc (HLI), a precision health intelligence company, has launched a new initiative offering $1 million to each qualified member who is later diagnosed with high-grade, potentially fatal prostate cancer. The offer is part of a broader effort to highlight the importance of proactive screening and early detection.
The program is open to male U.S. citizens aged 40–70 who are new members of HLI’s 100+ longevity program and meet all qualification criteria. Participants must complete all required screening tests and evaluations, which include non-invasive imaging and lab work designed to detect early indicators of life-threatening disease.
HLI states that its goal is to shift healthcare from reactive to preventive, using advanced diagnostics and personalized data to catch disease before symptoms appear. The initiative focuses on prostate cancer as a leading cause of cancer-related death among men in the U.S., aiming to raise awareness and encourage broader participation in early detection practices.
The company emphasizes that while not every case of prostate cancer is preventable, many can be detected early when treatment outcomes are more favorable. The $1 million pledge underscores HLI’s confidence in its technology and approach to identifying high-risk conditions before they progress.
The initiative is currently limited to a select number of participants, with details available on HLI’s official website.
